Class Action Lawsuit Filed Against Alto Neuroscience, Inc.

Bronstein, Gewirtz & Grossman, LLC has notified investors that a class action lawsuit has been filed against Alto Neuroscience, Inc. (NYSE: ANRO) and certain of its officers. The lawsuit alleges that defendants made material false and misleading statements regarding the company's initial public offering and the effectiveness of its treatment for major depressive disorder. Investors who purchased or acquired Alto common stock between February 2, 2024, and October 22, 2024, may be eligible to join the case.

Key Takeaways:

• The lawsuit was filed on behalf of investors who purchased or acquired Alto common stock during the class period of February 2, 2024, to October 22, 2024.
• Defendants are alleged to have made material false and misleading statements regarding the company's initial public offering and the effectiveness of its treatment for major depressive disorder.
• The lawsuit alleges that the company's Offering Documents were negligently prepared and contained untrue statements of material fact.
• Alto's business and financial prospects were overstated, resulting in investors suffering losses.
• The firm is representing investors on a contingency fee basis, and there is no cost to the investor.

Statistics:

• February 2, 2024: The date of Alto's initial public offering.
• October 22, 2024: The end date of the class period for the lawsuit.
• $332-239-2660: The phone number to contact Peretz Bronstein or Nathan Miller for more information.
• 9/19/2025: The deadline for requesting appointment as lead plaintiff.

Sources:

• Newsfile Corp., "Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Lawsuit Against Alto Neuroscience, Inc.", August 4, 2025.